CAR T-Cell Therapy Market

The global CAR T-Cell Therapy Market, Global Outlook and Forecast 2024-2030 generated an estimated USD 6.4 billion in 2025, with USD 7.6 billion in 2026 and a forecast of USD 20.6 billion by 2034, equivalent to a 13.3% CAGR across 2026–2034.

CAR T-cell medicines are engineered T lymphocytes that recognize an antigen on malignant cells. Commercial revenue comprises manufacturer sales of approved autologous CAR-T products targeting CD19 or BCMA, including lymphoma, leukemia and multiple myeloma indications. Sales recorded by distribution partners are not counted a second time. Experimental dual-target, allogeneic and solid-tumor candidates enter the forecast only once products become commercially available; research grants and licensing milestones do not represent therapy sales.

Gilead reported USD 1.8 billion of cell therapy sales in 2025, comprising Yescarta and Tecartus. Legend Biotech disclosed about USD 1.9 billion of global CARVYKTI net trade sales, while Bristol Myers Squibb recorded USD 1.358 billion for Breyanzi and USD 427 million for Abecma. These disclosed product revenues already exceed older estimates of the entire global CAR-T category; increasing manufacturing output and earlier-line indications support a larger sales base.

In the United States, the FDA broadened CARVYKTI eligibility in April 2024 after at least one previous myeloma regimen and approved Breyanzi for marginal zone lymphoma on 4 December 2025. In June 2025 the FDA removed separate REMS programs for six autologous CD19- and BCMA-directed products, reducing certification administration while requiring appropriate toxicity monitoring. These changes affect the speed at which treatment centers can offer an infusion, although patient-specific manufacturing still constrains capacity.

European and Asian access is widening unevenly. EMA documentation confirms the expanded Carvykti label and multiple Breyanzi indications; Japan lists its approved regenerative therapies through PMDA; and China authorized a CARVYKTI product in February 2025. Each indication expands the clinically eligible population, but collection capacity, payer decisions, bridging therapy and hospital beds determine the proportion reaching infusion. North American commercial prices continue to give the region the largest revenue position.

Source: Gilead 2025 results; BMS 2025 results; Legend 2025 Form 10-K; FDA REMS update.

Manufacturer net sales of approved CAR-T infusions provide the revenue measure; the analysis also examines hospital capacity, regulatory indications and pipeline technologies without treating clinical-stage program funding as medicine sales.

Earlier-line treatment expands eligible myeloma volume

The FDA extended the CARVYKTI indication on 5 April 2024 to selected patients after at least one prior myeloma therapy rather than only late relapse. Earlier use increases the pool able to reach leukapheresis before further clinical deterioration. Legend reported about USD 1.9 billion of CARVYKTI trade sales for 2025 and more than 10,000 cumulative patients treated by March 2026. Manufacturing slot availability still influences scheduling, while competing bispecific antibodies give clinicians an immediately available alternative when disease progresses quickly.

Lymphoma label expansion supports wider clinical referral

Breyanzi received additional U.S. lymphoma indications, including marginal zone lymphoma on 4 December 2025; the EMA also lists mantle cell and follicular lymphoma among its permitted uses. The broader eligible population can raise center throughput without introducing an entirely new manufacturing platform. Bristol Myers Squibb reported USD 1.358 billion in 2025 Breyanzi revenue, indicating that existing commercial infrastructure can support rapid expansion following labeling changes. Follow-up monitoring and bridging treatment still limit the speed of conversion from referral to infusion.

Patient-specific manufacturing creates a scaling bottleneck

Commercial CAR-T treatment begins with cell collection, followed by genetic modification, expansion, release testing and shipping back to the treating center. Each autologous batch is assigned to one patient, making factory scheduling sensitive to failed batches and unpredictable patient readiness. CARVYKTI reached 294 sites worldwide in March 2026, highlighting the need to coordinate international distribution and qualified infusion teams. Automated production and additional manufacturing sites could increase capacity, but a shortened manufacturing interval requires validated product comparability and clinical quality controls.

Toxicity management and reimbursement restrain uptake

Autologous CAR-T products can cause cytokine release syndrome, neurological adverse events, infections and prolonged cytopenias. In April 2024 the FDA strengthened boxed warnings concerning T-cell malignancies following CD19- or BCMA-directed treatment, with long-term safety follow-up remaining mandatory. Large upfront therapy prices are accompanied by inpatient care, apheresis and patient travel costs. Payer authorizations and treatment-center capacity therefore limit real-world access even after product approval, particularly in markets without established national funding pathways. FDA postmarketing requirements also create clinical surveillance costs after the patient leaves the treating center, adding financial pressure beyond the initial infusion.

Sources: FDA CARVYKTI and Breyanzi; FDA 2024 safety communication; Legend Biotech FY2025; Bristol Myers Squibb FY2025.

Regulators streamline selected center certification requirements

On 27 June 2025, the U.S. FDA announced elimination of separate REMS requirements for six autologous CAR-T products after determining that program-specific certification was no longer required. FDA product labels and adverse-event management obligations remain in place after the June 2025 decision. Removing duplicate paperwork can make the treatment pathway more manageable for qualified hospitals, but it does not eliminate the clinical need for early recognition of immune effector cell-associated neurotoxicity or cytokine release syndrome. Lower administrative barriers could help established centers add further products to their treatment offering.

China and Japan extend the addressable commercial geography

China authorized an autologous CARVYKTI product in February 2025 for adults with relapsed or refractory multiple myeloma after at least three prior regimens. Japan PMDA records approvals for Breyanzi, CARVYKTI and multiple other CAR-T products, establishing a local regulatory route for hospital adoption. These decisions provide manufacturers with pathways outside the U.S. and EU markets. Eligibility conditions, reimbursement and local manufacturing capacity differ sharply across countries, so an approval alone does not imply equal revenue per treated patient.

New CD19 and BCMA constructs compete on access and persistence

The U.S. FDA lists Autolus Aucatzyl among licensed cellular and gene therapy products, adding a CD19-directed treatment option for adult acute lymphoblastic leukemia. Meanwhile, Arcellx and Kite are evaluating anitocabtagene autoleucel, and allogeneic CAR-T developers are studying donor-derived cells. New products must compare on response durability, manufacturing reliability and safety against established incumbents. Payers may prefer therapies with longer follow-up and accessible specialized centers over products offering only early response-rate improvements from small uncontrolled cohorts.

International hospital networks expand specialist delivery capacity

European Medicines Agency medicine pages require specialist treatment settings and describe education about neurological toxicity and cytokine release syndrome. Japan has approved multiple CAR-T regenerative medicines, while Anvisa lists registered CARVYKTI, Kymriah and Yescarta in Brazil. Hospital networks can use experience from one autologous product when training staff for further CAR-T brands, although brand-specific handling remains necessary. Wider geographic coverage reduces patient travel, but ongoing costs for intensive monitoring and cryogenic logistics constrain adoption in smaller hospitals.

Licensed CAR-T medicines primarily recognize CD19 in B-cell malignancies or BCMA in multiple myeloma. Individual branded treatments differ in co-stimulatory domains, manufacturing arrangements, labeled prior therapies and eligible disease subtypes. Cross-trial response comparisons cannot replace randomized head-to-head evidence, because enrolled populations and follow-up periods differ.

The FDA listed six established CD19- and BCMA-directed autologous CAR-T medicines when it removed REMS programs in June 2025. These include Abecma, Breyanzi, CARVYKTI, Kymriah, Tecartus and Yescarta. The regulator separately lists Aucatzyl among licensed cellular products. CARVYKTI also uses an autologous product with BCMA recognition rather than an allogeneic off-the-shelf source. A qualified treatment facility handles collection and lymphodepleting chemotherapy before infusion, with monitoring for adverse inflammatory reactions.

Bristol Myers Squibb reported USD 1.358 billion in 2025 Breyanzi revenue, while Abecma contributed USD 427 million. This mix illustrates diverging commercial momentum across tumor indications and competitors, even within the same corporate manufacturing infrastructure. Gilead reported USD 1.5 billion of Yescarta sales and USD 344 million from Tecartus. Manufacturers are adding sites and manufacturing capacity to preserve treatment opportunities when patients need urgent therapy after conventional regimens.

Next-generation dual-target and allogeneic approaches aim to limit antigen escape or reduce the waiting period between eligibility and infusion. The clinical programs remain distinct from licensed product sales, and neither early remission rates nor a phase 1 study establishes an approved indication. The FDA continues to require prolonged monitoring for late adverse events with integrating-vector cellular therapies. Product differentiation consequently depends on long-term outcomes, toxicity control, local capacity and evidence useful to national payer agencies.

By target family, CD19-directed products serve lymphoma and leukemia whereas BCMA-directed products serve relapsed multiple myeloma. The 2025 commercial mix reflects established branded sales, not research grant allocations. CARVYKTI and Abecma label expansion increases BCMA exposure, while multiple CD19 products retain broad lymphoma access across major markets.

Lymphoma accounts for the greatest commercial use, while multiple myeloma grows with earlier-line CARVYKTI and Abecma eligibility. Acute lymphoblastic leukemia forms a narrower patient category; other indications are handled separately rather than added twice under lymphoma.

Infusions are coordinated through accredited or otherwise qualified hospital teams that can manage cytokine release syndrome and neurotoxicity. Organizational names differ by country, but the end-user classification separates broad hospital systems, dedicated cancer treatment centers and academic investigators that administer approved products.

Antigen-count categories distinguish existing one-target products from dual- and multi-antigen research designs. A bicistronic or tandem CAR construct is not equivalent to a single-target CD19 medicine even when both are made from autologous cells. This separation prevents clinical pipeline valuations from being added to 2025 commercial sales.

North America leads manufacturer revenue because U.S. treatment centers and reimbursement support branded CAR-T infusion; Europe and Asia-Pacific add approved populations under different hospital-funding and manufacturing arrangements.

CAR-T access depends on labeled eligibility, the manufacturer price of the cellular product, inpatient and outpatient services, and the availability of an accredited or otherwise qualified treating center. A regulator authorizes a medicine; a payer separately decides its coverage and conditions.

In the United States, the FDA eliminated separate REMS programs for six autologous CAR-T medicines in June 2025 while leaving product labeling and clinical monitoring requirements in effect. Specialized hospitals continue to coordinate infusion, tocilizumab availability and prompt management of neurologic and inflammatory toxicities. Insurers generally evaluate both the licensed disease stage and the treatment provider, delaying authorization despite FDA approval. Manufacturer product revenue excludes the payer cost of associated hospital and diagnostic services, preventing the same patient episode from inflating the CAR-T sales total.

European medicine access requires EMA authorization and a separate national reimbursement decision. The EMA grants marketing authorization for an advanced therapy medicinal product, while national reimbursement authorities determine where and for which patients it can be funded. EMA Carvykti documentation permits specified relapsed or refractory myeloma patients after one previous therapy, subject to other conditions. Breyanzi includes several B-cell lymphoma subtypes, but coverage may lag a newly expanded label. Manufacturer revenue consequently differs across countries even when the same European regulatory license applies.

In Asia-Pacific, Japan PMDA product approvals and the China NMPA conditional authorization of CARVYKTI in 2025 demonstrate formal regulatory options outside Europe and North America. Access still requires reliable apheresis, cell-manufacturing logistics and qualified inpatient monitoring. Latin American health systems face greater financing and geographic barriers, illustrated by Brazil having product registrations while specialist access remains concentrated. Additional sales growth depends on hospitals and payers converting these regulatory permissions into completed treatment episodes rather than approvals alone.

Source: FDA REMS decision; EMA Carvykti; PMDA.

CAR-T regulation covers target-antigen indications, individualized manufacturing, adverse-event labeling and long-term follow-up. Product-specific indication extensions have expanded approved populations since 2024, while donor-derived and multi-antigen designs remain in clinical development.

The FDA required boxed warnings for possible T-cell malignancies following BCMA- and CD19-directed autologous CAR-T products in April 2024. Integrating-vector products retain prolonged follow-up obligations because some adverse events can emerge after the initial infusion episode. Companies manufacturing living cellular medicines must also control batch identity, potency and release testing. Failure to deliver a personalized lot on schedule can postpone treatment and cause loss of an eligible patient when disease progresses during the manufacturing interval.

The European Medicines Agency Carvykti documentation records conversion from conditional to standard marketing authorization in April 2024. Breyanzi received additional European indications through subsequent assessments, creating multiple lymphoma routes. Japan PMDA publishes regulatory review histories for CAR-T products, enabling local clinicians to assess authorized populations. These regulatory milestones support commercial access, but comparative value assessments and national budgets still influence patient volumes and manufacturer net prices.

Dual-target approaches are being studied in clinical research, including a 2025 publication on CD19/CD22 CAR-T in patients with B-cell malignancies. Clinical activity also continues in allogeneic platforms intended to shorten waiting time for individualized manufacturing. Such programs should not be presented as approved or given marketed-product revenue before authorization. The 2034 outlook depends on whether developers can demonstrate reproducible clinical benefit, manageable toxicity and an efficient manufacturing system against increasingly established CD19 and BCMA standards.

Gilead/Kite, Bristol Myers Squibb and Janssen/Legend accounted for most disclosed 2025 CAR-T product sales across lymphoma and multiple myeloma. Gilead reported USD 1.8 billion in cell therapy product revenue, Bristol Myers Squibb reported USD 1.358 billion for Breyanzi and USD 427 million for Abecma, and Legend disclosed about USD 1.9 billion of CARVYKTI trade sales. Joint-commercialization receipts and collaboration revenue must not be added to the same product sales twice.

Gilead said 2025 Yescarta sales were USD 1.5 billion and Tecartus sales were USD 344 million, showing that CD19 commercial returns vary substantially by disease population. Bristol Myers Squibb reported rapid Breyanzi revenue growth in 2025, while its Abecma growth was more constrained. Expansion into earlier disease stages can increase annual patient starts, but aggressive competition for transplant-center slots and reimbursement contracts means total CAR-T revenue does not rise at the same rate for every brand.

CAR-T manufacturing agreements combine intellectual property licenses, centralized cell production and product-specific distribution. A company that receives royalty or collaboration income from a co-marketed therapy cannot add that receipt to the original product net trade sale when measuring the overall therapy market. Competition increasingly centers on production capacity and outcomes in treated patients, while academic clinical networks investigate new antigen targets.

• Gilead Sciences, Inc. (Kite Pharma)
• Bristol Myers Squibb Company
• Johnson & Johnson (Janssen Biotech)
• Legend Biotech Corporation
• Novartis AG
• Autolus Therapeutics plc
• JW Therapeutics
• Fosun Kite Biotechnology
• IASO Biotherapeutics
• Allogene Therapeutics, Inc.
• Arcellx, Inc.
• CARSgen Therapeutics Holdings Limited

Worldwide approved CAR-T product sales are projected to rise from USD 7.6 billion in 2026 to USD 20.6 billion in 2034, a 13.3% CAGR as existing CD19 and BCMA franchises add earlier-line patients and manufacturing capacity.

Commercial expansion is sensitive to throughput, not simply to cancer incidence. In 2025, Legend reported CARVYKTI sales of about USD 1.9 billion and more than 10,000 cumulative treated patients by March 2026; Gilead sold USD 1.8 billion of cell therapies across Yescarta and Tecartus. Greater cell-manufacturing capacity may allow earlier-line patients to receive treatment before rapid disease progression prevents infusion. Net product prices, hospital reimbursement and patient eligibility rules will moderate revenue growth despite rising treatment volume.

Indication expansion should broaden the approved populations within hematologic cancers. U.S. FDA actions in April 2024 brought both CARVYKTI and Abecma into earlier multiple myeloma lines; a December 2025 decision added marginal zone lymphoma to Breyanzi. Europe, Japan and China have their own authorization routes and treatment conditions. A manufacturer can leverage familiar manufacturing platforms as it introduces new indications, although a specialist hospital still needs product-specific coordination and payer approval for each patient.

Dual-antigen CAR-T constructs and donor-derived technologies are being evaluated to reduce antigen-negative relapse or waiting time. Published research on CD19/CD22 approaches shows ongoing development, but outcomes from small cohorts do not guarantee later marketing authorization. Forecast revenue allocated to the existing target groups remains more defensible than treating the entire investigational pipeline as sold therapy. Companies may introduce additional products before 2034 if late-stage trials, process validation, safety monitoring and reimbursement negotiations succeed.

Asia-Pacific could gain revenue from China approvals and PMDA-listed Japanese products, while EU revenue is determined by national funding decisions after EMA authorization. Brazil has product registrations but specialist delivery capacity remains concentrated, and Gulf health systems must build clinical and cold-chain infrastructure. Consequently, the forecast allows volume growth in regions with more approved products without allocating national revenue on population alone. Manufacturer sales exclude chemotherapy, ward fees and external royalties to maintain a consistent sales boundary.

Coverage includes worldwide manufacturer sales of approved cellular medicines, pipeline differentiation, country-level regulatory access and treatment infrastructure over 2025–2034.